Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Ophthalmic disease

Diabetic retinopathy

Cysteine-rich angiogenic inducer 61 (CYR61; CCN1)

Patient and mouse studies suggest targeting CCN1 and its degradation products could help treat proliferative diabetic retinopathy. In patients with proliferative diabetic retinopathy, vitreal fluid samples showed higher levels of a truncated, two-domain CCN1 variant than samples from nondiabetic individuals. In mouse models for retinopathy, overexpression of the full-length, four-domain CCN1 or a truncated, three-domain variant decreased pathological ischemia-induced neovascularization compared with expression of a control vector, whereas vector-mediated expression of the truncated, two-domain variant increased pathological neovascularization. Next steps include studies in additional patient samples to determine if clinical parameters of diabetic retinopathy correlate with qualitative and quantitative changes in CCN1.

SciBX 6(30); doi:10.1038/scibx.2013.801
Published online Aug. 8, 2013

Patent application filed; licensing details available from the SUNY Downstate Medical Center Office of Scientific Affairs and Biotechnology

Choi, J. et al. J. Biol. Chem.;
published online June 24, 2013;
doi:10.1074/jbc.M113.475418
Contact: Brahim Chaqour, SUNY Downstate Medical Center, Brooklyn, N.Y.
e-mail:
bchaqour@downstate.edu